J Korean Thyroid Assoc.  2014 May;7(1):57-61.

Hashimoto's Thyroiditis and Papillary Thyroid Cancer

Affiliations
  • 1Department of Surgery, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea. khnam@yuhs.ac

Abstract

The association of Hashimoto's thyroiditis (HT) with papillary thyroid cancer (PTC) has been still under debate. Some suggest that these two are positively correlated, whereas other studies report no relationship. We performed a systematic literature review of original studies to investigate the correlation between HT and PTC. The existing data provide inconsistent evidence favoring a causal relationship between HT and PTC. The average prevalence rate of PTC in patients with HT was 1.2% in 8 fine needle aspiration (FNA) studies of 18,023 specimens and 27.6% in 8 archival thyroidectomy studies of 9884 specimens. The risk ratio of PTC in HT specimens ranged from 0.39 to 1.00 in the FNA group (average RR 0.69) in contrast to 1.15 to 4.16 from thyroidectomy studies (average RR 1.59). Population-based fine needle aspiration biopsy studies report no relationship, whereas many of the studies using thyroidectomy specimens report a positive relationship, possibly related to selection bias. Several studies identified a few biomolecular markers, including the PI3K/Akt pathway, RET/PTC gene rearrangements, p63 protein, and loss of heterozygosity of hOGG1, that are potentially involved in neoplastic transformation from HT to PTC. So far, no causal genetic linkage has been confirmed. PTC with concurrent HT is associated with female gender, young age, less aggressive disease such as small tumor size, less frequent capsular invasion and nodal metastasis, and better outcome. However, more prospective studies with long term follow-up are needed to further elucidate this relationship and prognosis. Careful observation and follow-up of HT patients is recommended, especially those with nodular variants.

Keyword

Hashimoto's thyroiditis; Papillary thyroid cancer; Prevalence; Risk ratio; Prognosis

MeSH Terms

Biopsy
Biopsy, Fine-Needle
Female
Gene Rearrangement
Genetic Linkage
Humans
Loss of Heterozygosity
Neoplasm Metastasis
Odds Ratio
Prevalence
Prognosis
Selection Bias
Thyroid Gland*
Thyroid Neoplasms*
Thyroidectomy
Thyroiditis*

Figure

  • Fig. 1. Papillary thyroid carcinoma arising in the background of Hashimoto's thyroiditis. Lymphocytic infiltration with germinal center (thin arrow) and papillary carcinoma (thick arrow) are noted (H&E stain, X40).


Reference

References

1. Mazokopakis EE, Tzortzinis AA, Dalieraki-Ott EI, Tsartsalis AN, Syros PK, Karefilakis CM. et al. Coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma. A retrospective study. Hormones (Athens). 2010; 9(4):312–7.
2. Cipolla C, Sandonato L, Graceffa G, Fricano S, Torcivia A, Vieni S. et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg. 2005; 71(10):874–8.
3. Anderson L, Middleton WD, Teefey SA, Reading CC, Langer JE, Desser T. et al. Hashimoto thyroiditis: Part 2, sonographic analysis of benign and malignant nodules in patients with diffuse Hashimoto thyroiditis. AJR Am J Roentgenol. 2010; 195(1):216–22.
4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA;2006; 295(18):2164–7.
Article
5. Hanafusa T, Pujol-Borrell R, Chiovato L, Russell RC, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigen on thyrocytes in Graves’ disease: relevance for autoimmunity. Lancet. 1983; 2(8359):1111–5.
Article
6. Todd I, Pujol-Borrell R, Hammond LJ, Bottazzo GF, Feldmann M. Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol. 1985; 61(2):265–73.
7. Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. 1996; 335(2):99–107.
Article
8. Salmaso C, Bagnasco M, Pesce G, Montagna P, Brizzolara R, Altrinetti V. et al. Regulation of apoptosis in endocrine autoimmunity: insights from Hashimoto's thyroiditis and Graves’ disease. Ann N Y Acad Sci. 2002; 966:496–501.
9. Spencer CA. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab. 2011; 96(12):3615–27.
10. Shih ML, Lee JA, Hsieh CB, Yu JC, Liu HD, Kebebew E. et al. Thyroidectomy for Hashimoto's thyroiditis: complications and associated cancers. Thyroid. 2008; 18(7):729–34.
11. Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg. 1955; 70(2):291–7.
Article
12. Crile G Jr, Hazard JB. Incidence of cancer in struma lymphomatosa. Surg Gynecol Obstet. 1962; 115:101–3.
13. Crile G Jr. Struma lymphomatosa and carcinoma of the thyroid. Surg Gynecol Obstet. 1978; 147(3):350–2.
14. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985; 312(10):601–4.
Article
15. Carson HJ, Castelli MJ, Gattuso P. Incidence of neoplasia in Hashimoto's thyroiditis: a fine-needle aspiration study. Diagn Cytopathol. 1996; 14(1):38–42.
Article
16. Erdogan M, Erdem N, Cetinkalp S, Ozgen AG, Saygili F, Yilmaz C. et al. Demographic, clinical, laboratory, ultrasonographic, and cytological features of patients with Hashimoto's thyroiditis: results of a university hospital of 769 patients in Turkey. Endocrine. 2009; 36(3):486–90.
17. Matesa-Anic D, Matesa N, Dabelic N, Kusic Z. Coexistence of papillary carcinoma and Hashimoto's thyroiditis. Acta Clin Croat. 2009; 48(1):9–12.
18. Anil C, Goksel S, Gursoy A. Hashimoto's thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid. 2010; 20(6):601–6.
Article
19. Mukasa K, Noh JY, Kunii Y, Matsumoto M, Sato S, Yasuda S. et al. Prevalence of malignant tumors and adenomatous lesions detected by ultrasonographic screening in patients with autoimmune thyroid diseases. Thyroid. 2011; 21(1):37–41.
20. Ott RA, Calandra DB, McCall A, Shah KH, Lawrence AM, Paloyan E. The incidence of thyroid carcinoma in patients with Hashimoto's thyroiditis and solitary cold nodules. Surgery. 1985; 98(6):1202–6.
21. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008; 150(1):49–52.
Article
22. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S. et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg. 2007; 204(5):764–73. discussion 73-5.
23. Kurukahvecioglu O, Taneri F, Yuksel O, Aydin A, Tezel E, Onuk E. Total thyroidectomy for the treatment of Hashimoto's thyroiditis coexisting with papillary thyroid carcinoma. Adv Ther. 2007; 24(3):510–6.
Article
24. Bradly DP, Reddy V, Prinz RA, Gattuso P. Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery. 2009; 146(6):1099–104.
Article
25. Siriweera EH, Ratnatunga NV. Profile of Hashimoto's thyroiditis in Sri Lankans: is there an increased risk of ancillary pathologies in Hashimoto's thyroiditis? J Thyroid Res. 2010; 2010:124264.
Article
26. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery. 1999; 126(6):1070–6. discussion 6-7.
Article
27. Tamimi DM. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol. 2002; 10(2):141–6.
Article
28. McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab. 2012; 97(8):2682–92.
Article
29. Mechler C, Bounacer A, Suarez H, Saint Frison M, Magois C, Aillet G. et al. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Br J Cancer. 2001; 85(12):1831–7.
30. Unger P, Ewart M, Wang BY, Gan L, Kohtz DS, Burstein DE. Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link? Hum Pathol. 2003; 34(8):764–9.
Article
31. Royer MC, Zhang H, Fan CY, Kokoska MS. Genetic alterations in papillary thyroid carcinoma and hashimoto thyroiditis: An analysis of hOGG1 loss of heterozygosity. Arch Otolaryngol Head Neck Surg. 2010; 136(3):240–2.
32. Kebebew E, Treseler PA, Ituarte PH, Clark OH. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg. 2001; 25(5):632–7.
Article
33. Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z. et al. Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg. 2013; 148(3):396–402.
34. Muzza M, Degl’Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S. et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf). 2010; 72(5):702–8.
35. Jeong JS, Kim HK, Lee CR, Park S, Park JH, Kang SW. et al. Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome. J Korean Med Sci. 2012; 27(8):883–9.
36. Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbassat CA. Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis. J Clin Endocrinol Metab. 2013; 98(6):2409–2409.
Article
Full Text Links
  • JKTA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr